The firm said it is tackling challenges in its Diagnostics business, which had 2 percent growth year over year on a comparable basis in its fiscal fourth quarter.
Newly appointed interim CEO Thierry Bernard attempted to assuage investors' fears in the wake of a tumultuous month for Qiagen.
Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.
The firm saw modest growth across both of its business segments and double-digit growth in its droplet digital PCR product line.
The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The company reported increase US and international revenues and test volumes, driven by increased adoption and expanding public and private payor coverage.
The lowered guidance is due to continued expected weakness in China, exacerbated by the company's decision to halt the development of new next-generation sequencing instruments.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.